·247wallst.comLow
Hims & Hers (HIMS) Drops Nearly 12% in a Single Session
Hims & Hers (HIMS) shares fell nearly 12% in a day, erasing about $600 million in market value. The stock's volatility and valuation are now under scrutiny.
StockNYSE · US · USDHealthcare · Drug Manufacturers - Specialty & Generic
$HIMS
Hims & Hers Health, Inc.
Hims & Hers is a consumer health and wellness platform that connects customers with licensed healthcare professionals through websites and mobile applications. It provides access to telehealth consultations, personalized treatment plans, prescription medications, non-prescription products, laboratory testing, educational programs, wellness content and community support. Its offerings address conditions including sexual health, hair loss, hormone health, weight loss, dermatology and mental health. The company serves customers in the United States, Canada, the United Kingdom and parts of the European Union. Hims & Hers sells prescription medications, over-the-counter drugs and devices, cosmetics, supplements and testing services. Most prescriptions are fulfilled through its wholly owned pharmacies, with some products handled by partner pharmacies. Many offerings are sold through recurring subscriptions; customers are billed according to their chosen shipment or treatment cadence. The company also sells some non-prescription products through retail partnerships, in stores and online. It is headquartered in San Francisco, California.
AlphAI earnings readSecond Quarter 2026 · AUG 10 · NEXT NOV 9Revenue of approximately $753 million, up 38% year-over-year in Q2 2026; raises full year 2026 revenue guidance to a range of $3.1 billion to $3.3 billion and updates Adjusted EBITDA guidance to a range of $275 million to $325 millionVerdict: mixedRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $HIMSvia TradingView
AI sentiment · 7d4 articles
- Bullish
- 0
- Neutral
- 1
- Bearish
- 3
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $196K 2 txs
Boughton Soleil2× · $196K
10b5-1 share of filings100%
Top stories · $HIMSMore →
·bankinfosecurity.com
Your Sex Life Is None of Meta's Business
Meta (FB) is accused of receiving sensitive health data from Hims & Hers (HIMS) for advertising. Hims & Hers argues users agreed to data sharing in its terms of service. Hims & Hers reported 2.9M subscribers and $753M revenue in Q2 2026, with a $7B market valuation. Regulators allege misleading privacy practices.
·mlex.com
US FTC lawsuit against Hims & Hers appears headed for trial
A US federal judge ruled the FTC's lawsuit against Hims & Hers, alleging privacy and consumer protection violations, will likely proceed to trial. The case centers on the telehealth company's practices.
HIMS sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning HIMS (Hims & Hers Health, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 3 bearish.
Recent HIMS coverage spans regulation, market movers and financial news.
In the last 30 days, HIMS insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($196K). The most active reporter was Boughton Soleil, Chief Legal Officer, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving HIMS
The sharp intraday drop suggests heightened short‑term selling pressure.
Regulatory lawsuit could weigh on Hims & Hers valuation.
The lawsuit introduces regulatory risk that could depress HIMS stock.
Regulatory leniency could enable new revenue streams from peptide products.
The clearance removes a regulatory hurdle, likely supporting further upside.
AlphAI scores every news story that mentions HIMS with an AI model for sentiment and relevance, and aggregates insider trades from Hims & Hers Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $HIMS
Score
Hims & Hers (HIMS) Drops Nearly 12% in a Single Session
Hims & Hers (HIMS) shares fell nearly 12% in a day, erasing about $600 million in market value. The stock's volatility and valuation are now under scrutiny.
Your Sex Life Is None of Meta's Business
Meta (FB) is accused of receiving sensitive health data from Hims & Hers (HIMS) for advertising. Hims & Hers argues users agreed to data sharing in its terms of service. Hims & Hers reported 2.9M subscribers and $753M revenue in Q2 2026, with a $7B market valuation. Regulators allege misleading privacy practices.
US FTC lawsuit against Hims & Hers appears headed for trial
A US federal judge ruled the FTC's lawsuit against Hims & Hers, alleging privacy and consumer protection violations, will likely proceed to trial. The case centers on the telehealth company's practices.
Weekly Rundown: Doximity launches DoseCheck; AI recommends costlier care than doctors, study finds
Doximity launched DoseCheck, a safety feature for AI-based medication dosing, claiming 99% accuracy. Hims & Hers plans a peptides specialty after HHS policy change. Google introduced an AI education program for healthcare professionals. A study found AI models recommend costlier care than doctors, with higher testing and referral rates.
HIMS Stock Jumps 5% After HHS Temporarily Clears Compounding Of Six Peptides
HIMS stock rose 5% after HHS temporarily cleared the compounding of six peptides. The company faces an FTC lawsuit and margin pressures. Retail sentiment improved, with some users noting anticipation for earnings. HIMS stock is down 8% year-to-date. According to StockTwits, the clearance was seen as a positive development.
Hims & Hers Jumped 6% as RFK Jr.’s HHS Uses “Enforcement Discretion” to Open Peptide Compounding
Hims & Hers Health (HIMS) shares rose 6% after HHS announced enforcement discretion for six peptides, potentially benefiting Hims' peptide facility. The company awaits final FDA rules for a full launch. Hims' gross margin fell to 63.8% in Q2, with Q3 results on Nov. 9. Analysts estimate the peptide market at $2.2B-$3.3B, and Hims' revenue at $4.49B by 2028.
Can Hims & Hers Stock Fall 30%?
Hims & Hers Health (HIMS) shares fell 42.8% over the past year, and historical data suggests a further 30% drop is possible. The stock underperformed the S&P 500 in past market shocks, with an average decline of 37.0%. The company reported negative operating cash flow in Q2 2026, despite sales growth of 38.2%, and expects lower adjusted EBITDA for the fiscal year.
Hims Seeks Dismissal of FTC Suit Over User Data, Subscriptions
Hims & Hers Health Inc. asked a California judge to dismiss an FTC lawsuit alleging deceptive practices, improper data sharing, and difficult subscription cancellations. The company claims its privacy policy is clear and the FTC misapplied federal law. The FTC argues Hims violated a 2010 law requiring clear disclosure of subscription terms. Hims has 2.6 million subscribers. A hearing is scheduled for January 7.
Meta Stock Falls as Social Media Giant Faces New ‘Fraudulent’ Ads Lawsuit
Meta shares fell 7% to $648.68 as Rhode Island sued over alleged fraudulent ads. Hims & Hers faces an FTC lawsuit over subscription practices and data sharing, with a $60M legal reserve. Analysts have a Hold rating on HIMS, with an average target of $32.82. A court hearing is set for January 2027.
Hims expands testosterone treatment options with new products
Hims & Hers Health (NYSE:HIMS) launched new testosterone treatments, including injectable and oral options. The company cites growing demand, with 20M U.S. men affected by low testosterone. The expansion follows strong Q2 2026 performance, with testosterone treatments scaling faster than other specialties. A survey showed 79% of men prioritize energy over muscle, highlighting market potential. The products are not FDA-approved in all states.